Apolipoprotein C-III: From Pathophysiology to Pharmacology

Giuseppe Danilo Norata, Sotirios Tsimikas, Angela Pirillo, Alberico L. Catapano

Research output: Contribution to journalArticlepeer-review


Apolipoprotein C-III (apoC-III) has a critical role in the metabolism of triglyceride (TG)-rich lipoproteins (TRLs). Animal models lacking the APOC3 gene exhibit reduced plasma TG levels, whereas the overexpression of APOC3 leads to increased TG levels. In humans, loss-of-function mutations in APOC3 are associated with reduced plasma TG levels and reduced risk for ischemic vascular disease and coronary heart disease. Several hypolipidemic agents have been shown to reduce apoC-III, including fibrates and statins, and antisense technology aimed at inhibiting APOC3 mRNA to decrease the production of apoC-III is currently in Phase III of clinical development. Here, we review the pathophysiological role of apoC-III in TG metabolism and the evidence supporting this apolipoprotein as an emerging target for hypertriglyceridemia (HTG) and associated cardiovascular disorders.

Original languageEnglish
Pages (from-to)675-687
Number of pages13
JournalTrends in Pharmacological Sciences
Issue number10
Publication statusPublished - Oct 1 2015


  • coronary heart disease
  • lipoprotein lipase
  • remnant lipoproteins
  • Triglycerides

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology


Dive into the research topics of 'Apolipoprotein C-III: From Pathophysiology to Pharmacology'. Together they form a unique fingerprint.

Cite this